Tolmar Expands Operations with New Laboratory at Rosalind Franklin University

Rosalind Franklin University’s Innovation and Research Park (IRP) has officially welcomed the new Northern Illinois Laboratory for Tolmar, Inc., a specialty pharmaceutical company. This facility will enhance Tolmar’s ability to develop and commercialize pharmaceutical products while contributing to the university’s innovative ecosystem.

Founded in 2007, Tolmar is recognized globally for its advanced capabilities in long-acting injectable drug delivery. The company specializes in developing and manufacturing injectables for fields such as urology, oncology, and endocrinology. Notably, Tolmar’s leading product is utilized in the treatment of advanced prostate cancer and is marketed in 89 countries worldwide.

The establishment of this new research facility at Rosalind Franklin’s IRP represents not just a strategic expansion for Tolmar but also a significant boost to the regional presence of the company, which has executive offices and sales and marketing staff located in Buffalo Grove, Illinois.

Dr. Dave Loffredo, Tolmar’s Vice President of Innovation, expressed excitement about the new development capabilities that the laboratory will provide. He stated, “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”

Collaboration and Innovation Potential

Dr. Stace Porter, Senior Vice President of Development Operations for Tolmar, highlighted the collaborative opportunities that the new laboratory will afford. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores,” he noted. “Surrounded by Lake County’s vibrant network of global life science companies, we’re excited to grow and innovate here.”

The 100,000-square-foot IRP also houses six research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. Dr. Joseph DiMario, Executive Vice President for Research at RFU, welcomed Tolmar to the university’s roster of companies. He emphasized the potential for impactful collaborations, stating, “We look forward to collaborations that can help accelerate new product development. The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”

About Tolmar and Rosalind Franklin University

Tolmar is a fully integrated specialty pharmaceutical company focused on the development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas. The company operates product development and manufacturing facilities in Northern Colorado, while its executive offices and commercial headquarters are based in Buffalo Grove, Illinois.

Rosalind Franklin University of Medicine and Science embodies the spirit of inquiry and excellence represented by its namesake, Dr. Rosalind Franklin, whose Photo 51 was crucial to the discovery of the DNA structure. The university is recognized for its research in various fields, including neuroscience, diabetes, and obesity, and includes institutions such as the Chicago Medical School and the College of Health Professions.

For further details, visit www.tolmar.com and rosalindfranklin.edu.